Standard of the Dutch College of General Practitioners for the management of patients with myocardial infaction;NHG-standaard beleid na een doorgemaakt myocardinfarct

Huisarts en Wetenschap

Volumn 48, Issue 5, 2005, Pages 220-231

  Grundmeijer, H G L M ^a   Van Bentum, S T B ^a   Rutten, F H ^a   Bakx, J C ^a   Hendrick, I M A ^a   Bouma, M ^a   Eizenga, W H ^a   Verduijn, M M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN ANTAGONIST; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CAPTOPRIL; DIGOXIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; KETOCONAZOLE; MACROLIDE; NITRATE; PERINDOPRIL; PROTEINASE INHIBITOR; RAMIPRIL; SIMVASTATIN; TRANDOLAPRIL; VERAPAMIL;

GENERAL PRACTITIONER; HEART INFARCTION; HUMAN; LIVER DYSFUNCTION; MYOPATHY; NETHERLANDS; PRACTICE GUIDELINE; REVIEW; SIDE EFFECT; STANDARD;

EID: 18444394913     PISSN: 00187070     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (120)

1. Ades PA. Cardiac rehabilitation and secondary prevention of coronary heart disease. N Engl J Med 2001;345:892-902.
2. Aengevaeren WR, Bär F, Van Boven AI, Van't Hof AW, De Jaegere P, Jap W. The NVVC guidelines for the management of patients with ST-elevation acute coronary syndromes (STE-ACS). Netherlands Heart J 2002;10:125-35.
3. Anonymus. Cough caused by ACE inhibitors. Drug Ther Bull 1994;32:28.
4. Anonymus. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
5. Anonymus. Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Arch Intern Med 1998;158:1855-67.
6. Anonymus. Myocardial infarction redefined-a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Eur Heart J 2000;21:1502-13.
7. Anonymus. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial Lancet 2002;360:7-22.
8. AntithromboticTrialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients BMJ 2002;324:71-86.
9. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, et al. ACC/AHA guidelines For the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction) (2004). http://www.acc.org/clinical/guidelines/stemi/ index.pdf.
10. Aronow WS. Beta-blockers, angiotensin-converting enzyme inhibitors, and calcium antagonists in treatment of elderly patients with acute myocardial infarction Coron Artery Dis 2000;11:331-8.
11. Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med 2000;160:685-93.
12. Berkman LF, Blumenthal I, Burg M, Carney RM, Catellier D, Cowan MI, et al. Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) Randomized Trial. JAMA 2003;289:3106-16.
13. Birkenhäger WH, De Leeuw PW. Survival of the fittest: invloedvan geregelde lichaamsbeweging op gezondheid en levensverwachting. Ned Tijdschr Geneeskd 2002;146:1479-83.
14. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman IS, et al. ACC/AHA guideline update for management of patients with unstable angina and non-ST-segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (2002). http://www.acc.org/dinical/ guidelines/unstable/update_index. htm.
15. Braunwald E, Domanski MI, Fowler SE, Geller NL, Gersh BI, Hsia J, et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004;351:2058-68.
16. Brouwer MA, Van den Bergh PI, Aengevaeren WR, Veen G, Luijten HE, Hertzberger DP, et al. Aspirin plus coumarin versus aspirin alone in the prevention of reocclusion after fibrinolysis for acute myocardial infarction: results of the Antithrombotics in the Prevention of Reocclusion In Coronary Thrombolysis (APRICOT)-2 Trial. Circulation 2002;106:659-65.
17. Brown A, Taylor R, Noorani H, Stone I, Skidmore B. Exercise-based cardiac rehabilitation programs for coronary artery disease: a systematic clinical and economic review. Technology report no. 34 (2003). http://www.ccohta.ca.
18. Calle EE, Thun MI, Petrelli JM, Rodriguez C, Heath CW Jr. Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med 1999;341:1097-105.
19. Cannon CP, Braunwald E, McCabe CH, Rader DI, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504.
20. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-39.
21. Cleophas T, Kauw F, Van der Meulen I, Kalmansohn RB. De betekenis van bijkomende eigenschappen van bètablokkers. Pharm Weekbl 1998;133:1134-9.
22. Commissie Farmaceutische hulp. Farmacotherapeutisch Kompas. Amstelveen: College voor Zorgverzekeringen, 2005.
23. Critchley IA, Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review, JAMA 2003;290:86-97.
24. Dalal H, Evans PH, Campbell JL. Recent developments in secondary prevention and cardiac rehabilitation after acute myocardial infarction. BMJ 2004;328:693-7.
25. De Gier JJ. Commentaren Medicatiebewaking 2003-2004. Houten: Stichting Health Base, 2003.
26. De Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KA, White HD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004;292:1307-16.
27. De Waard DE, Kamp O, Visser FC, Visser CA. Angiotensine-'converting'- enzymremmers na een myocardinfarct: klinische en echocardiografische indicaties. Ned Tijdschr Geneeskd 1997;141:84-8.
28. DeBusk R, Drory Y, Goldstein I, Iackson G, Kaul S, Kimmel SE, et al. Management of sexual dysfunction in patients with cardiovascular disease: recommendations of The Princeton Consensus Panel. Am J Cardiol 2000;86:175-81.
29. Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002;360:752-60,
30. Doll R, Peto R, Wheatley K, Gray R, Sutherland I. Mortality in relation to smoking: 40 years observations on male British doctors. BMJ 1994;309:901-11.
31. Domanski MJ, Exner DV, Borkowf CB, Geller NL, Rosenberg Y, Pfeffer MA. Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction. A meta-analysis of randomized clinical trials. J Am Coll Cardiol 1999;33:598-604.
32. Downs IR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/ Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615-22.
33. Dusseldorp E, Van Elderen T, Maes S, Meulman I, Kraaij V. A meta-analysis of psychoeducational programs for coronary heart disease patients. Health Psychol 1999;18:506-19.
34. Fiore LD, Ezekowitz MD, Brophy MT. Warfarin combined with low dose aspirin in myocardial infarction did not provide clinical benefit beyond that of aspirin alone. EBM 2002;7:140.
35. Flather MD, Yusuf S, Kober L, Pfeffer M, Hall A, Murray G, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000;355:1575-81.
36. Freemantle N, Cleland I, Young P, Mason I, Harrison J. Beta Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999;318:1730-7.
37. Froelicher ES, Kee LL, Newton KM, Lindskog B, Livingston M. Return to work, sexual activity, and other activities after acute myocardial infarction. Heart Lung 1994;23:423-35.
38. Gezondheidsraad. Overgewicht en obesitas Den Haag: Gezondheidsraad, 2003.
39. Gibson RS, Hansen JF, Messerli F, Schechtman KB, Boden WE, Long-term effects of diltiazem and verapamil on mortality and cardiac events in non-Q-wave acute myocardial infarction without pulmonary congestion: post hoc subset analysis of the multicenter diltiazem postinfarction trial and the second danish verapamil infarction trial studies. Am J Cardiol 2000;86:275-9.
40. Gijsen R, Poos MIJC. Achtergronden en details bij cijfers uit huisartsenregistraties. Volksgezondheid toekomstverkenning: nationaal kompas volksgezondheid. Bilthoven: RIVM 2003.
41. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 1998;339:489-97.
42. Granger CB, Goldberg RJ, Dabbous O, Pieper KS, Eagle KA, Cannon CP, et al. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med 2003;163:2345-53.
43. Haywood LJ. Coronary heart disease mortality/morbidity and risk in blacks. I: Clinical manifestations and diagnostic criteria: he experience with the Beta Blocker Heart Attack Trial. Am Heart J 1984;108:787-93.
44. Hirsh J, Bhatt DL. Comparative benefits of clopidogrel and aspirin in high-risk patient populations: lessons from the CAPRIE and CURE studies. Arch Intern Med 2004;164:2106-10.
45. Honig A. Depressie na een hartinfarct en vergrote kans op overlijden Ned Tijdschr Geneeskd 2000;144:1307-10.
46. Houghton T, Freemantle N, Cleland IG. Are beta-blockers effective in patients who develop heart failure soon after myocardial infarction? A meta-regression analysis of randomised trials. Eur J Heart Fail 2000;2:333-40.
47. Howes LG, Tran D. Can angiotensin receptor antagonists be used safely in patients with previous ACE inhibitor-induced angioedema? Drug Saf 2002;25:73-6.
48. Hubert HB, Feinleib M, McNamara PM, Castell WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation 1983;67:968-77.
49. Hurlen M, Abdelnoor M, Smith P. Warfarin alone or with aspirin was superior to aspirin alone after acute myocardial infarction but increased bleeding. EBM 2003;8:42.
50. Ianssen I, Katzmarzyk PT, Ross R. Body mass index, waist circumference, and health risk: evidence in support of current National Institutes of Health guidelines. Arch Intern Med 2002;162:2074-9.
51. Jolliffe IA, Rees K, Taylor RS, Thompson D, Oldridge N, Ebrahim S. Exercise-based rehabilitation for coronary heart disease. Cochrane Database Syst Rev 2001;1:CD001800.
52. Kanamasa K, Hayashi T, Takenaka T, Kimura A, Ikeda A, Ishikawa K. Chronic use of continuous dosing of long-term nitrates does not prevent cardiac events in patients with severe acute myocardial infarction. Cardiology 2000;94:139-45.
53. Kanamasa K, Hayashi T, Kimura A, Ikeda A, Ishikawa K. Long-term, continuous treatment with both oral and transdermal nitrates increases cardiac events in healed myocardial infarction patients, Angiology 2002;53:399-408
54. Kawachi I, Colditz GA, Stampfer MJ, Willett WC, Manson IE, Rosner B, et al. Smoking cessation and time course of decreased risks of coronary heart disease in middle-aged women. Arch Intern Med 1994;154:169-75.
55. Kerst AIFA. Charm-offensief tegen hartfalen. Gebu 2004;38:29-31.
56. Koek HL, Bots ML. Hartinfarct: cijiers en feiten. Den Haag: Nederlandse Hartstichting, 2004
57. Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie. Informatorium Medicamentorum (Combirom). Den Haag: KNMP, 2005.
58. Linden W, Stossel C, Maurice J, Psychosocial interventions for patients with coronary artery disease: a meta-analysis. Arch Intern Med 1996;156:745-52.
59. Lonn E, Gerstein HC, Smieja M, Mann IFE, Yusuf S. Mechanisms of cardiovascular risk reduction with ramipril: insights from HOPE and HOPE substudies Eur Heart J 2003;5 suppl A:43-8.
60. Lonn EM, Yusuf S, Iha P, Montague TJ, Teo KK, Benedict CR, et al. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation 1994;90:2056-69
61. Ltd B. What are the effects of antithrombotic treatment? Clin Evid 2004;11:202-9.
62. Mathus-Vliegen EM. Voedingen gezondheid - streefgewicht bij obesitas niet realistisch: wel gezondheidswinst door matige stabiele gewichtsreductie. Ned Tijdschr Geneeskd 2003;147:1168-72.
63. McAlister FA, Lawson FM, Teo KK, Armstrong PW, Randomised trials of secondary prevention programmes in coronary heart disease: systematic review. BMI 2001;323:957-62
64. Mehta SR, Yusuf S, Peters RI, Bertrand ME, Lewis BS, Natarajan MK, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358:527-33.
65. Messerli FH, Hansen JF, Gibson RS, Schechtman KB, Boden WE. Heart rate-lowering calcium antagonists in hypertensive post-myocardial infarction patients. J Hypertens 2001;19:977-82.
66. Moller J, Ahlbom A, Hulling I, Diderichsen F, De Faire U, Reuterwall C, et al. Sexual activity as a trigger of myocardial infarction. A case-crossover analysis in the Stockholm Heart Epidemiology Programme (SHEEP). Heart 2001;86:387-90.
67. Muller JE, Mittleman A, Maclure M, Sherwood IB, Tofler GH. Triggering myocardial infarction by sexual activity. Low absolute risk and prevention by regular physical exertion. Determinants of Myocardial Infarction Onset Study Investigators. JAMA 1996;275:1405-9.
68. Murchie P, Campbell NC, Ritchie LD, Simpson IA, Thain J. Secondary prevention clinics for coronary heart disease: four year follow up of a randomised controlled trial in primary care. BMJ 2003;326:84.
69. Must A, Spadano I, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. JAMA 1999;282:1523-9.
70. Nauta ILD. Plaatsbepaling calciumantagonisten bij cardiovasculaire aandoeningen. Gebu 1996;30:51-7.
71. Nederlandse Hartstichting. Prognose van patiënten met een eerste ziekhuisopname wegens net acuut hartinfarct in Nederland Hart- en vaatziekten in Nederland 2004. Den Haag: Nederlandse Hartstichting. 2004.
72. NHG. DKB-Stoppen met roken-cahier Utrecht: NHG, 2000.
73. NICE. Guideline on prophylaxis for patients who have experienced a myocardial infarction (2001). http://www.nice.org.uk.
74. Parker JD, Parker JO. Nitrate therapy for stable angina pectoris. N Engl J Med 1998;338:520.
75. Pedersen SS, Denollet J. Type D personality, cardiac events, and impaired quality of life: a review. Eur J Cardiovasc Prev Rehabil 2003;10:241-8.
76. Pepine CJ, Faich G, Makuch R. Verapamil use in patients with cardiovascular disease: an overview of randomized trials. Clin Cardiol 1998;21:633-41.
77. Pfeffer MA, McMurray II, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893-906.
78. Pignone M, Rihal C, Ltd B. Secondary prevention of ischaemic cardiac events. Clin Evid 2004;12:219-20.
79. Reikvam A, Madsen S, Landmark K. [Secondary prevention after acute myocardial infarction: aspirin, warfarin or both?]. Tidsskr Nor Laegeforen 2003;123:1838-40.
80. Remkes PAJ, Branbergen HCT, Bongers FJM. Werkafspraken en verwijsbeleid tussen huisarts en cardioloog. Hart Bulletin 2000;31:137-43.
81. Rengo F, Carbonin P, Pahor M, DeCaprio L, Bernabei R, Ferrara N, et al. A controlled trial of verapamil in patients after acute myocardial infarction: results of the calcium antagonist reinfarction Italian study (CRIS). Am J Cardiol 1996;77:365-9.
82. Revalidatiecommissie NHS/NVVC. Richtlijn Hartrevalidatie 2004. Den Haag: Nederlandse Hartstichting, 2004.
83. Rozanski A, Blumenthal JA, Kaplan J. Impact of psychological factors on the pathogenesis of cardiovascular disease and implications for therapy. Circulation 1999;99:2192-217.
84. Rutten FH, Grundmeijer HGLM, Grijseels EWM, Van Bentum STB, Hendrick JMA, Bouma M. NHG-Standaard Acuut coronair syndroom. Huisarts Wet 2003;46:831-43.
85. Ruwaards D, Kramers PGN. Volksgezondheid toekomstverkenning 1997: de som der delen. Utrecht: Elsevier/De Tijdstroom, 1997.
86. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335:1001-9.
87. Salpeter S, Ormiston T, Salpeter E, Poole P, Cates C. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2002a;2:CD003566.
88. Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for reversible airway disease. Cochrane Database Syst Rev 2002b;4:CD002992.
89. Schers H, Van de Ven C, Van den Hoogen H, Grol R, Van den Bosch W. Patients' needs for contact with their GP at the time of hospital admission and other life events: a quantitative and qualitative exploration. Ann Fam Med 2004;2:462-8.
90. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001;285:1711-8.
91. Scottish Intercollegiate Guidelines Network (SIGN). Secundary prevention of coronary heart disease (2000). http://www.sign.ac.uk.
92. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7.
93. Sica DA, Black HR. Current concepts of pharmacotherapy in hypertension: ACE inhibitor-related angioedema: can angiotensin-receptor blockers be safely used? J Clin Hypertens (Greenwich) 2002a;4:375-80.
94. Sica DA, Black HR. Angioedema in heart failure: occurrence with ACE inhibitors and safety of angiotensin receptor blocker therapy. Congest Heart Fail 2002b;8:334-41, 345.
95. Smith SC Jr., Blair SN, Bonow RO, Brass LM, Cerqueira MD, Dracup K, et al. AHA/ACC Scientific Statement: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: A statement for healthcare professionals from the American Heart Associa-tion and the American College of Cardiology. Circulation 2001;104:1577-9.
96. Soriano JB, Hoes AW, Meems L, Grobbee DE. Increased survival with beta-blockers: importance of ancillary properties. Prog Cardiovasc Dis 1997;39:445-56.
97. Stampfer MI, Hu FB, Manson JE, Rimm EB, Willett WC. Primary prevention of coronary heart disease in women through diet and lifestyle. N Engl J Med 2000;343:16-22.
98. Taylor RS, Brown A, Ebrahim S, Jolliffe J, Noorani H, Rees K, et al. Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials. Am J Med 2004;116:682-92.
99. Teo KK, Yusuf S, Furberg CD, Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials. JAMA 1993;270:1589-95.
100. The beta-blockers pooling project research group. The beta-blocker pooling project (BBPP): subgroup findings from randomized trials in post infarction patients. Eur Heart J 1988;9:8-16
101. The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-8.
102. The heart outcomes prevention evaluation study investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. New Engl J Med 2000;342:145-53.
103. Toenders WGM. Omega-3-vetzuren (Omacor®). CFH-rapport04/13 (2004). http://www.cvz.nl. 2004.
104. Van Bentum STB, Meulepas M. Verschuivende zorg: huisarts neemt stabiele hartpatiënten onder zijn hoede. Med Cont 2004;47:1869-72.
105. Van de Werf F, Ardissino D, Betriu A, Cokkinos DV, Falk E, Fox KA, et al. Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2003;24:28-66.
106. Van der Elst ME, Buurma H, Bouvy ML, De Boer A. Drug therapy for prevention of recurrent myocardial infarction. Ann Pharmacother 2003;37:1465-77.
107. Van der Ent M. De medicamenteuze behandeling tijdens en na het myocardinfarct. Gebu 2003;37:13-9.
108. Van Domburg RT, Deckers JW. Identificatie van postinfarctpatiënten met een laag risico op mortaliteit. Hart Bulletin 1999;30:9-13.
109. Van Es RF, Jonker JJ, Verbeugt FW, Deckers JW, Grobbee DE. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet 2002;360:109-13.
110. Van Melle JP, De Jonge P, Spijkerman TA, Tijssen JG, Ormel J, Van Veldhuisen DI, et al. Prognostic association of depression following myocardial infarction with mortality and cardiovascular events: a meta-analysis. Psychosom Med 2004;66:814-22.
111. Van Wijngaarden J, Van Veldhuisen DJ, De Graeff PA, De behandeling van angina pectoris met nitraten. Ned Tijdschr Geneeskd 1996;140:819-22,
112. Velazquez EI, Pfeffer MA, McMurray JV, Maggioni AP, Rouleau JL, Van de Werf. VALsartan In Acute myocardial INfarcTion (VALIANT) trial: baseline characteristics in context. Eur J Heart Fail 2003;5:537-44.
113. Verheugt FWA. Preventie en behandeling van coronaire trombose met bloedplaatsjesaggregatieremmers. Gebu 2002;36:133-9.
114. Warner KK, Visconti JA, Tschampel MM. Angiotensin II receptor blockers in patients with ACE inhibitor-induced angioedema. Ann Pharmacother 2000;34:526-8.
115. Westerweel PE, Verhaar MC, Rabelink TI. Pleiotrope effecten van statinen. Ned Tijdschr Geneeskd 2004;148:1431-5.
116. White HD. Should all patients with coronary disease receive angiotensin-converting-enzyme inhibitors? Lancet 2003;362:755-7.
117. Wilt TI, Bloomfield HE, MacDonald R, Nelson D, Rutks I, Ho M, et al. Effectiveness of statin therapy in adults with coronary heart disease. Arch Intern Med 2004;164:1427-36.
118. Yusuf S, Lonn E, Anti-ischaemic effects of ACE inhibitors: review of current clinical evidence and ongoing clinical trials. Eur Heart J 1998;19 Suppl 1:136-144.
119. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation N Engl J Med 2001;345:494-502.
120. Zock PL, Kromhout D. Voeding en gezondheidvisvetzuren tegen fatale coronaire hartziekten. Ned Tijdschr Geneeskd 2002;146:2229-33.